Clinical trials: Advanced Cancers of the Prostate
Breast Cancer, Colorectal Cancer
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
RATIONALE: Sorafenib and pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00703638
- Testing
- cisplatin, pemetrexed disodium, sorafenib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Breast Cancer, Prostate Cancer
Reducing Dexamethasone Around Docetaxel Infusion
The manufacturer recommends two different regimens of prophylactic dexamethasone to prevent hypersensitivity and fluid retention reactions caused by docetaxel: a 3-day regime of dexamethasone 8mg twice a day starting the day…
- Trial name
- REDEX (NCT02776436)
- Testing
- Dexamethasone, Prednisone
- Where
- 3 sites in Netherlands
- Volunteers
- 46 people
- Sponsor
- Leiden University Medical Center
Prostate Cancer
Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer
The purpose of this study is to determine if the drug dutasteride increases expression of genes that slow the growth of prostate cancer during treatment with intermittent androgen ablation therapy (hormone therapy).
- Trial name
- NCT00668642
- Testing
- Dutasteride
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Endeavor Health
Locally Advanced Prostate Cancer, Oligometastatic Prostate Cancer
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
To evaluated the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer.
- Trial name
- SEGNO (NCT06387056)
- Testing
- Rezvilutamide, Goserelin Microspheres for Injection, Docetaxel
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Breast Cancer, Prostate Cancer
Potential Vertebroplasty Use in the Treatment of Vertebral Metastasis From Breast and Prostate Cancer
The study aims to evaluate if adding vertebroplasty to radiotherapy, in the treatment of spine metastasis from breast and prostate cancer, is preferable to radiotherapy alone.
- Conditions
- Breast Cancer, Prostate Cancer, Vertebral Metastasis, Pain
- Trial name
- NCT00294151
- Testing
- Vertebroplasty
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Metastatic Castration Resistant Prostate Cancer, mCRPC
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
The goal of this clinical trial is to find out if FX-111 is safe enough to permit further studies in adult male participants with metastatic castration-resistant prostate cancer (mCRPC).
- Conditions
- Metastatic Castration Resistant Prostate Cancer, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostatic Neoplasms
- Trial name
- NCT07719361
- Testing
- FX-111
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Flare Therapeutics Inc.
Localized Prostate Carcinoma, Locally Advanced Cervical Carcinoma
Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers
This phase II trial studies how well time-restricted eating works in reducing side effects of radiation or chemoradiation side effects when compared to nutritional counseling among patients with prostate, cervical, and rectal…
- Conditions
- Localized Prostate Carcinoma, Locally Advanced Cervical Carcinoma, Locally Advanced Rectal Carcinoma, Malignant Solid Neoplasm
- Trial name
- NCT05722288
- Testing
- Biospecimen Collection, Informational Intervention, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- City of Hope Medical Center
Intermediate Risk Prostate Cancer, Castration-resistant Prostate Cancer
VAccination in Early and ADvanced Prostate caNCEr
This is a clinical trial of a new treatment for prostate cancer that is a type of vaccine that could be a new way to treat cancer.
- Trial name
- ADVANCE (NCT03815942)
- Testing
- ChAdOx1-MVA 5T4 vaccine, Nivolumab Infusion [Opdivo]
- Where
- 2 sites in United Kingdom
- Volunteers
- 23 people
- Sponsor
- University of Oxford
Advanced Solid Tumor, Cholangiocarcinoma
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors (solid tumor, BTC and…
- Conditions
- Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer
- Trial name
- NCT05253053
- Testing
- TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel
- Where
- 9 sites in China
- Volunteers
- 84 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Prostate Cancer
Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer
Evaluation of the effectiveness of weekly docetaxel/bortezomib as first-line chemotherapy for patients with advanced hormone-refractory prostate cancer.
- Trial name
- NCT00193232
- Testing
- Docetaxel, Bortezomib
- Volunteers
- 50 people
- Sponsor
- SCRI Development Innovations, LLC
Prostate Cancer, Adenocarcinoma of the Prostate
Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer
Objective was to evaluate the efficacy and safety of the histrelin acetate subdermal implant (originally versus Lupron Depot-3 Month) in male patients with advanced prostate cancer during 52 weeks of treatment with the implant.
- Trial name
- NCT01697384
- Testing
- histrelin acetate
- Volunteers
- 138 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Advanced Prostate Cancer, Metastatic Prostate Cancer
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or metastatic prostate cancer.
- Trial name
- NCT05800665
- Testing
- RO7656594
- Where
- 26 sites in United States, Australia and 5 more
- Volunteers
- 210 people
- Sponsor
- Genentech, Inc.
Prostate Cancer
Sarcopenia in Older Patient With Prostate Cancer, Prevalence and Incidence After Androgen Deprivation Therapy
Prostate cancer is the most common cancer among men 50 years and older and mainly affets patients 75 years old. Androgen deprivation therapy is indicatated in intermediates and high risks form of prostate cancer, in association…
- Trial name
- HoSAGE (NCT04484246)
- Testing
- Prevalence of sarcopenia in older patient with prostate cancer
- Where
- France
- Volunteers
- 112 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Advanced Cancer
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer.
- Trial name
- NCT04148937
- Testing
- LY3475070, Pembrolizumab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
Cancer
Gene Therapy in Treating Patients With Cancer
RATIONALE: Inserting a gene that has been created in the laboratory into a person's white blood cells may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00004178
- Testing
- therapeutic autologous lymphocytes
- Where
- United States
- Sponsor
- Roger Williams Medical Center
Stage III Prostate Cancer
Omega-3 Fatty Acids in Treating Patients With Advanced Prostate Cancer
This phase I trial is studying the best way to give omega-3 fatty acids in treating patients with advanced prostate cancer. Omega-3 fatty acids may slow disease progression and may be an effective treatment for patients with…
- Trial name
- NCT00996749
- Testing
- omega-3 fatty acid, bone scan, dual x-ray absorptometry
- Sponsor
- Wake Forest University Health Sciences
Liposarcoma, Prostate Cancer
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and in combination with endocrine therapy.
- Conditions
- Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- CDK4i (NCT04557449)
- Testing
- PF-07220060, Letrozole, Fulvestrant
- Where
- 39 sites in United States, Argentina and 6 more
- Volunteers
- 430 people
- Sponsor
- Pfizer
Prostate Cancer
A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer
The purpose of this open-label, single-arm, multicenter, post-marketing trial is to evaluate long-term safety of Firmagon® in approximately 230 Indian patients diagnosed with advanced hormone-dependent prostate cancer requiring…
- Trial name
- NCT02726009
- Testing
- Degarelix
- Where
- 19 sites in India
- Volunteers
- 230 people
- Sponsor
- Ferring Pharmaceuticals
NSCLC, Prostate Cancer
Clinical Trial of TB511 in Advanced Solid Tumors
1. Study population [TB511 Monotherapy Cohort for Phase 1 and Phase 2a Clinical Trial] Patients with advanced solid tumors who are either refractory or intolerant to standard of care (SoC).
- Conditions
- NSCLC, Prostate Cancer, Colorectal Cancer, Hepatocellular Carcinoma
- Trial name
- NCT06400160
- Testing
- TB511, Keytruda
- Volunteers
- 12 people
- Sponsor
- Twinpig Biolab, Inc.
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health